Feature

Not all lung cancer patients receive treatment


 

In the United States, just over 15% of patients with lung cancer receive no treatment, according to the American Lung Association.

Percentage of people with lung cancer who received no treatment

“This can happen for multiple reasons, such as the tumor having spread too far, poor health, or refusal of treatment,” the ALA said in its 2019 State of Lung Cancer report.

On the state level, the disparities were considerable. Arizona had the highest rate of nontreatment at 30.4%, followed by the neighboring states of New Mexico (24.2%) and California (24.0%). The lowest rate in the country, 8.0%, came from North Dakota, with Missouri next at 9.4% and Maine third at 9.6%, based on data from the North American Association of Central Cancer Registries’ December 2018 data submission, which covered the years from 2012 to 2016.

Although some cases of lung cancer may be unavoidable, “no one should go untreated because of lack of provider or patient knowledge, stigma associated with lung cancer, fatalism after diagnosis, or cost of treatment. Dismantling these and other barriers is important to reducing the percent of untreated patients,” the ALA said.

Recommended Reading

Patients have good recall on lung cancer screening scan benefits, not risks
MDedge Hematology and Oncology
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
MDedge Hematology and Oncology
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
MDedge Hematology and Oncology
Fluoroscopic system can improve targeting of lung lesions
MDedge Hematology and Oncology
Nivolumab benefit for NSCLC persists at 5-year follow-up
MDedge Hematology and Oncology
Lung cancer on the decline, but still higher among men than women
MDedge Hematology and Oncology
Atezolizumab bests chemo in NSCLC patients with high PD-L1 expression
MDedge Hematology and Oncology
‘You had me at hello’: ESMO studies confirm survival benefits in NSCLC and breast cancer
MDedge Hematology and Oncology
Lorlatinib induces deep responses in ROS1-positive NSCLC
MDedge Hematology and Oncology
Neoantigen vaccine appears safe and active in NSCLC
MDedge Hematology and Oncology